secwatch.observer — SEC 8-K summary
======================================

Issuer:     Travere Therapeutics, Inc. (TVTX)
CIK:        0001438533
Form:       8-K/A
Filed at:   2025-05-01T23:59:59+00:00
Accession:  0001438533-25-000030
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.01, 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Travere Q1 2025 net product sales $75.9M, FILSPARI U.S. sales up 182% YoY; net loss narrows to $41.2M
--------------------------------------------------------------------------------

- FILSPARI U.S. net product sales $55.9M in Q1 2025, up 182% YoY; 703 new patient start forms received.
- Net loss of $41.2M ($0.47/share) vs $136.1M ($1.76) in Q1 2024; non-GAAP net loss $16.9M ($0.19).
- sNDA for full approval of FILSPARI in FSGS submitted March 2025; FDA acceptance decision expected May 2025.
- European Commission converted FILSPARI to standard MA for IgAN; expects $17.5M milestone from CSL Vifor in Q2 2025.
- Cash, cash equivalents, and marketable securities $322.2M as of March 31, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1438533/000143853325000030/0001438533-25-000030-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1438533/000143853325000030/tvtx-20250501.htm
  HTML page:      https://secwatch.observer/filing/0001438533-25-000030

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer